Full Text Journal Articles by
Author Hideki Hagiwara

Advertisement

Find full text journal articles






Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.

Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji Yamamoto, Masahide Oshita, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Toshifumi Ito, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara, ,

<h4>Background</h4>Several factors associated with hepatocellular carcinoma (HCC) occurrence after sustained virological response (SVR) in patients with hepatitis C have been reported. However, few validation studies have been performed in the era of direct-acting anti-virals (DAAs).<h4>Aims</h4>To develop a prediction model for HCC occurrence after DAA-mediated SVR and validate its usefulness.<h4>Methods</h4>We analysed ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Shinji Tamura, Hideki Hagiwara, Eiji Mita, Takayuki Yakushijin, Masami Inada, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background/aim</h4>The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml.<h4>Patients and methods</h4>In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, ... Read more >>

Anticancer Res (Anticancer research)
[2021, 41(4):2187-2192]

Cited: 0 times

View full text PDF listing >>



Advertisement

Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Masahide Oshita, Hideki Hagiwara, Mitsuru Sakakibara, Shinji Tamura, Naoki Hiramatsu, Masami Inada, Sadaharu Iio, Toshifumi Ito, Takayuki Yakushijin, Yoshinori Doi, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>The aim of the present study was to investigate the clinical course in hepatitis C virus (HCV)-positive patients with decompensated liver cirrhosis after direct-acting antivirals (DAAs) have been used for HCV infection.<h4>Methods</h4>This multicenter study prospectively analyzed a registered cohort composed of 73 HCV-positive patients with decompensated cirrhosis who attended our ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2021, 51(5):517-527]

Cited: 0 times

View full text PDF listing >>



Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>It remains unclear how direct-acting antiviral (DAA) treatments influence hepatocellular carcinoma (HCC) recurrence and survival in comparison with interferon (IFN).<h4>Methods</h4>In total, 338 patients with chronic hepatitis C virus (HCV) infection and previous HCC treatments who initiated IFN (N = 88, IFN group) or DAA treatment (N = 250, DAA group) from January 2005 to ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(10):1118-1127]

Cited: 1 time

View full text PDF listing >>



Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Ayako Urabe, Yuki Tahata, Masahide Oshita, Kazuyoshi Ohkawa, Eiji Mita, Hideki Hagiwara, Shinji Tamura, Toshifumi Ito, Takayuki Yakushijin, Sadaharu Iio, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. This study evaluated the therapeutic efficacy of lenvatinib in patients with poor liver function with and without portal hypertension.<h4>Methods</h4>This prospectively registered ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(9):1091-1100]

Cited: 0 times

View full text PDF listing >>



Nationwide epidemiological survey of chronic pancreatitis in Japan: introduction and validation of the new Japanese diagnostic criteria 2019.

Atsushi Masamune, Kazuhiro Kikuta, Kiyoshi Kume, Shin Hamada, Ichiro Tsuji, Yoshifumi Takeyama, Tooru Shimosegawa, Kazuichi Okazaki, ,

<h4>Objectives</h4>To provide updated clinico-epidemiological information on chronic pancreatitis (CP) in Japan.<h4>Methods</h4>We conducted a two-stage nationwide epidemiological survey; the number of CP patients was estimated in the first-stage survey, and their clinical features were examined in the second-stage survey. We surveyed patients with CP who had visited hospitals in 2016 and ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2020, 55(11):1062-1071]

Cited: 3 times

View full text PDF listing >>



Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.

Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background</h4>L31 and Y93 in the NS5A region of the hepatitis C virus (HCV) are the most important substitution positions associated with resistance to direct-acting antiviral (DAA) treatment.<h4>Methods</h4>We analyzed the frequency of NS5A L31M/V and Y93/H in NS5A inhibitor-naive HCV genotype 1 patients who received asunaprevir plus daclatasvir combination treatment using ... Read more >>

PLoS One (PloS one)
[2020, 15(6):e0234811]

Cited: 0 times

View full text PDF listing >>



Clinical practice of acute pancreatitis in Japan: An analysis of nationwide epidemiological survey in 2016.

Atsushi Masamune, Kazuhiro Kikuta, Shin Hamada, Ichiro Tsuji, Yoshifumi Takeyama, Tooru Shimosegawa, Kazuichi Okazaki, ,

<h4>Background</h4>To provide updates on clinical practice of acute pancreatitis (AP) in Japan, we conducted a nationwide epidemiological survey.<h4>Methods</h4>This study consisted of a two-staged survey; the number of AP patients was estimated by the first-stage survey and their clinical features were examined by the second-stage survey. We surveyed AP patients who ... Read more >>

Pancreatology (Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.])
[2020, 20(4):629-636]

Cited: 2 times

View full text PDF listing >>



Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Taizo Hijioka, Shinji Tamura, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Several studies have recently reported that hepatocellular carcinoma (HCC) occurrence does not differ between hepatitis C virus patients receiving interferon (IFN)-based and IFN-free treatments considering the patients' backgrounds. However, liver fibrosis was not directly considered in these studies.<h4>Methods</h4>In total, 3972 patients without a history of HCC who started IFN-based or IFN-free ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):313-320]

Cited: 0 times

View full text PDF listing >>



Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016.

Atsushi Masamune, Kazuhiro Kikuta, Shin Hamada, Ichiro Tsuji, Yoshifumi Takeyama, Tooru Shimosegawa, Kazuichi Okazaki, ,

<h4>Background</h4>To further clarify the clinico-epidemiological features of autoimmune pancreatitis (AIP) in Japan, we conducted the fourth nationwide epidemiological survey.<h4>Methods</h4>This study consisted of two stage surveys; the number of AIP patients was estimated by the first survey and their clinical features were assessed by the second survey. We surveyed the AIP ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2020, 55(4):462-470]

Cited: 12 times

View full text PDF listing >>



Efficacy of chemotherapy for older patients with gastric cancer: a multicenter retrospective cohort study.

Yoshito Hayashi, Tsutomu Nishida, Shusaku Tsutsui, Takashi Ohta, Shinjiro Yamaguchi, Masayoshi Horimoto, Eiji Masuda, Hiroyuki Narahara, Aya Sugimoto, Yoshiki Tsujii, Kunio Suzuki, Hideki Hagiwara, Hideki Iijima, Tetsuo Takehara,

<h4>Background</h4>Gastric cancer is one of the leading causes of malignant disease-related mortality, worldwide. With the use of recently developed anti-tumor agents, the prognoses of patients with unresectable gastric cancer are improving. However, the development of an aggressive treatment strategy for older patients (OPs) remains under debate due to concerns regarding ... Read more >>

Int J Clin Oncol (International journal of clinical oncology)
[2019, 24(11):1377-1384]

Cited: 0 times

View full text PDF listing >>



Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.

Ayako Urabe, Ryotaro Sakamori, Yuki Tahata, Ryoko Yamada, Yasuharu Imai, Hideki Hagiwara, Shinji Tamura, Hiroyuki Fukui, Yukinori Yamada, Akira Kaneko, Taizo Hijioka, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Sofosbuvir (SOF) and ribavirin (RBV) combination therapy has improved the sustained virologic response (SVR) rate and shortened the treatment duration for patients with chronic hepatitis C virus (HCV) genotype 2 infection. Ribavirin-induced hemolytic anemia is one of the most troublesome side-effects of SOF/RBV therapy; however, factors associated with this condition ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(8):853-859]

Cited: 0 times

View full text PDF listing >>



[Endoscopic treatment for gastric carcinoid tumor in a patient with type A gastritis complicated with autoimmune polyendocrine syndrome: a case report].

Takafumi Mie, Takashi Ohta, Takayuki Iwamoto, Rui Mizumoto, Yuki Arimoto, Mayura Toda, Satoshi Shimizu, Shinjiro Yamaguchi, Yoshiki Ito, Hideki Hagiwara,

A 42-year-old female developed type 1 diabetes mellitus at the age of 16 years and received insulin therapy. Esophagogastroduodenoscopy revealed an atrophic change localized in the gastric body and a small, protruding gastric lesion. Biopsy revealed that this lesion was gastric neuroendocrine tumor. Hence, the patient underwent en bloc resection ... Read more >>

Nihon Shokakibyo Gakkai Zasshi (Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology)
[2019, 116(8):654-659]

Cited: 0 times

View full text PDF listing >>



Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

Ryoko Yamada, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Naoki Morishita, Takahiro Kodama, Hayato Hikita, Ryotaro Sakamori, Takayuki Yakushijin, Akira Yamada, Hideki Hagiwara, Eiji Mita, Masahide Oshita, Toshifumi Itoh, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Atsuo Inoue, Yasuharu Imai, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(5):570-578]

Cited: 7 times

View full text PDF listing >>



Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: A multicenter retrospective cohort study by the Osaka Gut Forum.

Motohiro Hirao, Masato Komori, Tsutomu Nishida, Hideki Iijima, Shinjiro Yamaguchi, Ryu Ishihara, Yuichi Yasunaga, Ichizo Kobayashi, Osamu Kishida, Masahide Oshita, Hideki Hagiwara, Toshifumi Ito, Kunio Suzuki, Yoshito Hayashi, Takahiro Inoue, Masahiko Tsujii, Harumasa Yoshihara, Tetsuo Takehara,

Primary small bowel adenocarcinoma (SBA) is a rare cancer for which effective treatment strategies have not yet been established. The results of previous retrospective studies suggest that chemotherapy contributes to a longer survival time in patients with SBA. However, there are few case reports about the efficacy of molecular targeted ... Read more >>

Oncol Lett (Oncology letters)
[2017, 14(2):1628-1636]

Cited: 3 times

View full text PDF listing >>



Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.

Yugo Kai, Hayato Hikita, Naoki Morishita, Kazuhiro Murai, Tasuku Nakabori, Sadaharu Iio, Hideki Hagiwara, Yasuharu Imai, Shinji Tamura, Syusaku Tsutsui, Masafumi Naito, Meiko Nishiuchi, Yasuteru Kondo, Takanobu Kato, Hiroshi Suemizu, Ryoko Yamada, Tsugiko Oze, Takayuki Yakushijin, Naoki Hiramatsu, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara,

Resistance-associated substitutions (RASs) in hepatitis C virus (HCV) appear upon failure of treatment with direct-acting antivirals (DAAs). However, their origin has not been clarified in detail. Among 11 HCV genotype 1b patients who experienced virologic failure with asunaprevir (ASV)/daclatasvir (DCV), 10 had major NS5A L31M/V-Y93H variants after treatment. L31M/V-Y93H variants ... Read more >>

Sci Rep (Scientific reports)
[2017, 7:41660]

Cited: 12 times

View full text PDF listing >>



Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.

Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Sadaharu Iio, Akira Yamada, Hideki Hagiwara, Eiji Mita, Yukinori Yamada, Toshifumi Ito, Masami Inada, Kazuhiro Katayama, Iwao Yabuuchi, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy.<h4>Methods</h4>The factors associated with the treatment effect, including RAVs in the NS3 ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2017, 47(8):773-782]

Cited: 2 times

View full text PDF listing >>



Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yukinori Yamada, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

The factors associated with sustained virologic response (SVR) in chronic hepatitis C (CH-C) genotype 1 patients treated with simeprevir (SMV), pegylated interferon (Peg-IFN) plus ribavirin (RBV) triple therapy have not been fully investigated. Two hundred and twenty-nine treatment-naïve CH-C patients treated with SMV triple therapy were enrolled in this study. ... Read more >>

J Med Virol (Journal of medical virology)
[2016, 88(10):1776-1784]

Cited: 1 time

View full text PDF listing >>



The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Ryoko Yamada, Takayuki Yakushijin, Eiji Mita, Hideki Hagiwara, Yukinori Yamada, Toshifumi Ito, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Keiko Irishio, Michio Kato, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>Hyperbilirubinemia, mild or moderate, is a commonly observed laboratory abnormality in chronic hepatitis C patients treated with simeprevir with pegylated interferon (Peg-IFN) plus ribavirin. In this prospective, multicenter study, we aimed to investigate the clinical features and factors associated with bilirubin increases during the therapy.<h4>Methods</h4>A total of 192 patients with ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2016, 51(3):252-259]

Cited: 7 times

View full text PDF listing >>



Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Akinori Kasahara, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara, ,

<h4>Background & aims</h4>In patients with chronic hepatitis C virus (HCV) infection, lack of sustained virologic response (SVR) 24 weeks after the end of interferon therapy is a significant risk factor for hepatocellular carcinoma (HCC). Although many pretreatment factors are known to affect HCC incidence, less is known about post-treatment factors-many ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2014, 12(7):1186-1195]

Cited: 47 times

View full text PDF listing >>



Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Sadaharu Iio, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>HCV kinetics during treatment demonstrated strong association with the antiviral outcome of patients treated with pegylated interferon (Peg-IFN) plus ribavirin. However, the relationship between HCV kinetics and pre-treatment factors remains unclear.<h4>Methods</h4>Of 547 patients with HCV genotype 1 treated with Peg-IFN alfa-2b plus ribavirin, 401 completed the response-guided therapy and were ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2014, 49(4):737-747]

Cited: 3 times

View full text PDF listing >>



Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.

Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, Ryoko Yamada, Mika Kurokawa, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Masahide Oshita, Eiji Mita, Hideki Hagiwara, Yoshiaki Inui, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Atsuo Inoue, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>This study was conducted to evaluate Japanese treatment guidelines for patients with chronic hepatitis C virus (HCV) infection and normal alanine aminotransferase (N-ALT) levels from the viewpoint of the incidence of hepatocellular carcinoma (HCC).<h4>Methods</h4>Four groups of patients with chronic HCV infection treated with pegylated interferon (Peg-IFN) plus ribavirin, and classified ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2013, 48(4):535-543]

Cited: 2 times

View full text PDF listing >>



Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

Tatsuya Kanto, Michiyo Inoue, Tsugiko Oze, Masanori Miyazaki, Mitsuru Sakakibara, Naruyasu Kakita, Tokuhiro Matsubara, Koyo Higashitani, Hideki Hagiwara, Sadaharu Iio, Kazuhiro Katayama, Eiji Mita, Akinori Kasahara, Naoki Hiramatsu, Tetsuo Takehara, Norio Hayashi,

<h4>Background</h4>For the treatment of chronic hepatitis C, a combination of pegylated interferon-α (PEG-IFNα) and ribavirin has been widely used as a standard of care. Enhancement of immune response against hepatitis C virus (HCV) is known to be involved in the efficacy of the combination therapy. Our aim was to elucidate ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2012, 47(2):169-178]

Cited: 8 times

View full text PDF listing >>



Determination of the absolute structure of (+)-akaterpin.

Hayato Hosoi, Nobuyuki Kawai, Hideki Hagiwara, Takahiro Suzuki, Atsuo Nakazaki, Ken-Ichi Takao, Kazuo Umezawa, Susumu Kobayashi,

We describe the total synthesis and structural determination of (+)-akaterpin (1), an inhibitor of phosphatidylinositol-specific phospholipase C (PI-PLC). The key features of the synthetic strategy include the resolution of β,γ-unsaturated ketone (±)-2a with chiral sulfoximine 6. The absolute stereochemistry was determined by comparison of the specific optical rotation data of ... Read more >>

Chem Pharm Bull (Tokyo) (Chemical & pharmaceutical bulletin)
[2012, 60(1):137-143]

Cited: 2 times

View full text PDF listing >>



Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.

Tsugiko Oze, Naoki Hiramatsu, Changho Song, Takayuki Yakushijin, Sadaharu Iio, Yoshinobu Doi, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Masanori Miyazaki, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara,

<h4>Background</h4>The timing to the first undetectable hepatitis C virus (HCV) RNA level is strongly associated with sustained virologic response in pegylated interferon (Peg-IFN) plus ribavirin combination therapy for patients with chronic hepatitis C (CH-C) with genotype 1. This study was conducted to clarify the impact of drug exposure to Peg-IFN ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2012, 47(3):334-342]

Cited: 2 times

View full text PDF listing >>



Advertisement


Disclaimer

4.3794 s